Donor exposure to the plasticizer di(2‐ethylhexyl)phthalate during plateletpheresis

Buchta, Christoph; Bittner, Claudia; Höcker, P; Macher, Maria; Schmid, Rainer; Seger, Christoph; Dettke, Markus

doi:10.1046/j.1537-2995.2003.00479.x

Cited by 33 publications

(28 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In adults, highest doses of DEHP may result by transfusions of blood components reaching up to several mg/kg/day. It has also been shown that apheresis procedures to donate blood products can cause significant exposure to DEHP [119][120][121]200]. Premature neonates in intensive care can receive even higher DEHP exposures relative to their bw compared with adults [116][117][118]133].…”

Section: Groups At Riskmentioning

confidence: 99%

Assessing exposure to phthalates – The human biomonitoring approach

Wittassek¹,

Koch

Angerer

et al. 2011

Molecular Nutrition Food Res

683

381

View full text Add to dashboard Cite

Some phthalates are developmental and reproductive toxicants in animals. Exposure to phthalates is considered to be potentially harmful to human health as well. Based on a comprehensive literature research, we present an overview of the sources of human phthalate exposure and results of exposure assessments with special focus on human biomonitoring data. Among the general population, there is widespread exposure to a number of phthalates. Foodstuff is the major source of phthalate exposure, particularly for the long-chain phthalates such as di(2-ethylhexyl) phthalate. For short-chain phthalates such as di-n-butyl-phthalate, additional pathways are of relevance. In general, children are exposed to higher phthalate doses than adults. Especially, high exposures can occur through some medications or medical devices. By comparing exposure data with existing limit values, one can also assess the risks associated with exposure to phthalates. Within the general population, some individuals exceed tolerable daily intake values for one or more phthalates. In high exposure groups, (intensive medical care, medications) tolerable daily intake transgressions can be substantial. Recent findings from animal studies suggest that a cumulative risk assessment for phthalates is warranted, and a cumulative exposure assessment to phthalates via human biomonitoring is a major step into this direction.

show abstract

Section: Groups At Riskmentioning

confidence: 99%

Assessing exposure to phthalates – The human biomonitoring approach

Wittassek¹,

Koch

Angerer

et al. 2011

Molecular Nutrition Food Res

683

381

View full text Add to dashboard Cite

show abstract

“…In a study focusing on donor exposure to DEHP during plateletpheresis, the blood of 36 healthy donors undergoing plateletpheresis with either continuous or discontinuous apheresis devices was collected, and the serum concentrations of DEHP were determined (Buchta et al 2003). In two other studies, DEHP exposure was assessed in 11 patients and 21 patients with chronic renal failure undergoing maintenance hemodialysis (Dine et al 2000; Faouzi et al 1999).…”

Section: Introductionmentioning

confidence: 99%

Evaluation of the Di(2-ethylhexyl)phthalate released from polyvinyl chloride medical devices that contact blood

et al. 2014

View full text Add to dashboard Cite

Extraction methods that simulate those used in the clinic are recommended for obtaining extraction solutions. For polyvinyl chloride (PVC) medical devices that have contact with human blood, an alternative medium (ethanol/water mixture) is suggested as an extraction screening vehicle to evaluate the di(2-ethylhexyl)phthalate (DEHP) released. A test comparing the extraction ability between the alternative medium and whole blood from three healthy volunteers has been conducted. An experimental method is provided outlining the chemical analysis of the DEHP released from medical devices made with polyvinyl chloride (PVC). Gas chromatography-mass spectrometry (GC-MS) in the selective ion monitoring (SIM) mode was used to analyze and quantify the extracted DEHP. The linear range of the SIM method was 0.1-200 μg/mL, and the recoveries were 89.6-101.5% and 91.0-98.9% when using the ethanol/water mixture and whole blood as the extraction media, respectively. The validated method demonstrates that it is suitable for the determination of the DEHP released from PVC medical devices that have contact with blood. The results from the determination of the DEHP released will be compared with the limits derived from toxicological data for the parenteral exposure route and certain population groups, and the results will be used in the risk assessment of medical devices.

show abstract

“…This may be because the lipid-rich plasma may contain most of the DEHP, which is removed from the body by the procedure. Buchta (2003) estimated from serum DEHP concentrations exposures of 1.8-20.3 µg/kg/d due to apheresis procedure. In fact, neonates receive higher doses, in terms of body weight, of DEHP than the general population (Calafat et al 2004b;Green et al 2005) and their daily dose to DEHP may increase up to 20 folds the tolerable daily intake (Jaeger et al 2005).…”

Section: Adult Exposure During Medical Proceduresmentioning

confidence: 99%

Plasticizer concentration in cord blood cryopreserved with DMSO

Yamaguchi

Takanashi

Ito

et al. 2013

Bone Marrow Transplant

View full text Add to dashboard Cite

The Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) has evaluated the exposure to DEHP for the general population and patients during medical procedures. In many cases the exposure is significant and exceeds the toxic doses observed in animal studies. There is limited evidence indicating a relation between DEHP exposures and certain effects in humans. However, it is recognised that especially the potentially high exposure during medical treatments raise a concern, even in the absence of clinical or epidemiological evidence, for harmful effects in humans. For certain uses of DEHP alternative plasticizers for PVC are available. The Committee got access to toxicity data for eight possible alternative plasticizers and compared their toxicity with that of DEHP. In respect to reproductive toxicity in animal studies DEHP induces more severe effects compared with some of the alternatives. A risk assessment of these available alternative plasticizers could not be performed due to a lack of exposure data from medical devices. Each alternative to DEHP, however, must also be evaluated with regard to their functionality in respect to medical devices. The risk and benefits of using alternative plasticizers should be evaluated case by case.

show abstract

Donor exposure to the plasticizer di(2‐ethylhexyl)phthalate during plateletpheresis

Abstract: Commercial plateletpheresis disposables release considerable amounts of DEHP during the apheresis procedure, but the total dose of DEHP retained by the donor is within the normal range of DEHP exposure of the general population.

Cited by 33 publications

References 29 publications

Assessing exposure to phthalates – The human biomonitoring approach

Assessing exposure to phthalates – The human biomonitoring approach

Evaluation of the Di(2-ethylhexyl)phthalate released from polyvinyl chloride medical devices that contact blood

Plasticizer concentration in cord blood cryopreserved with DMSO

Contact Info

Product

Resources

About